Pöördumine

Saatja: [email protected] Saaja: "Info - SOM" <[email protected]> Teema: [DKIM katki]Information request Kuupäev: 2026-01-07 09:18 Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. HOIATUS! See e-kiri võib olla liba-, õngitsus- või pahaloomuline, kuna on saadetud asutusest, kus meiliserver on vigaselt seadistatud. Rohkem infot: KKK | teenusveeb <https://teenused.rit.ee/et/kkk> -> E-post ja kalender. Dear Sir or Madam! On behalf of the Non-Melanoma Skin Cancers Task Force of the European Academy of Dermatology and Venereology I am preparing a report on disparities in access to oncological drugs for skin cancers in Europe. I was wondering if there is a chance to receive from you information how many patients were treated for non-melanoma skin cancer in Estonia in the last year with the following drugs: pembrolizumab, nivolumab, cemiplimab, retifanlimab, avelumab, vismodegib, sonidegib, cetuximab, imatinib. I would be grateful for information if these medications are reimbursed for patients with skin cancers and what are the rules for reimbursement. The information will be used to create a Europe-wide report on treatment accessibility to be published in the Journal of the European Academy of Dermatology and Venereology. I would be extremely grateful for help with obtaining this information. Best regards Marek Jankowski MD PhD Nicolaus Copernicus University, Torun, Poland